[ad_1]
On Monday, TV 2 wrote that the coronary vaccine produced by AstraZeneca and the University of Oxford had an average efficacy of about 70 percent.
During the large-scale trial, one group received two full doses of the vaccine, resulting in an efficiency of 62 percent.
The other group received a half dose of vaccine and then a full dose. The results of this group showed that the vaccine is about 90 percent effective.
“The discovery was a coincidence,” said Mene Pangalos, who is working to develop the vaccine at AstraZeneca, according to CNBC.
Tabbe
In April, shortly after AstraZeneca and the University of Oxford began collaborating on the vaccine, the trial phase of the vaccine was already underway.
During the test, it was discovered by chance that the expected side effects of the vaccine, such as fatigue, headaches and arm pain, were milder than expected.
– So we checked once more and found that the amount of vaccine had been cut in half by mistake, says Pangalos.
– We decided to continue using a test group with half doses. Yes, it was due to a mistake, according to Reuters.
Positive news
Both the Pfizer / BioNTech vaccine and the Moderna vaccine have been shown to be up to 95 percent effective against the virus.
But the AstraZeneca vaccine has a distinctive feature that can make it particularly important in fighting the pandemic.
Researcher in vaccine news: – Very good news
It does not need to be stored in extreme cold. It can be stored in the refrigerator, which makes it easy to distribute around the world.
The Pfizer / BioNTech vaccine, on the other hand, should be stored at minus 70 degrees Celsius, in a deep freezer, while the Moderna vaccine should be stored in a freezer.
– The Astra-Zeneca vaccine is therefore more suitable for distribution and is stimulating for everyone, vaccine researcher Gunnveig Grødeland told TV 2 on Monday.
